Thalidomide in multiple myeloma: current status and future prospects.
Cavenagh
Jamie D
JD
St Bartholomew's and The Royal London School of Medicine and Dentistry, London, UK.
Oakervee
Heather
H
D000014:Abnormalities, Drug-Induced; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000139:chemically induced; D011247:Pregnancy; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D013923:Thromboembolism / Q000139:chemically induced
D000276:Adjuvants, Immunologic; D020533:Angiogenesis Inhibitors; D016207:Cytokines; D005938:Glucocorticoids; D013792:Thalidomide; D003907:Dexamethasone